Proteomics and AI with Peter Cimermančič

What It Covers

Peter Cimermančič, cofounder of Tesserai and former seven-year Verily researcher, explains how AI-powered preprocessing of mass spectrometry proteomics data can recover up to 80% of currently unidentified spectra, unlocking drug targets and biological insights that conventional search algorithms systematically miss.

Key Questions Answered

• •The 80% Dark Matter Problem: Current mass spectrometry search algorithms leave up to 80% of measured spectra unidentified, meaning most proteomics-based drug discovery operates on only 20-30% of available data. Researchers should treat preprocessing quality — not downstream analytics — as the primary bottleneck limiting biological discovery and target identification accuracy.
• •Cloud Migration as Dual Solution: Moving proteomics preprocessing from single workstations to cloud infrastructure solves two problems simultaneously: parallelizing compute across hundreds of nodes accelerates processing speed, while the added compute capacity enables replacement of legacy rule-based algorithms with transformer and vision-based AI models that capture previously ignored signal.
• •Absence of Signal as Data: Current scoring algorithms match spectra using barcode-style peak matching, ignoring peak intensities, non-canonical fragmentation patterns, and crucially, the absence of expected peaks. AI models trained without these human-imposed rules learn from missing signal too, producing 70% more peptide identifications on standard human proteomes and 200-300% gains on complex metaproteomics datasets.
• •Expanding the Search Space: Standard proteomics searches only consider canonical proteins longer than 50 amino acids in unmodified form. Deliberately expanding searches to include small open reading frames, post-translational modifications, and sequence variants — enabled by a sufficiently accurate scoring model — reveals biologically relevant proteins that canonical pipelines structurally cannot detect.
• •Proteomics Covers the Full Drug Discovery Pipeline: Mass spectrometry proteomics applies across every drug discovery stage: affinity purification identifies protein-protein interactions for target discovery; chemoproteomics maps covalent small-molecule binding sites; immunopeptidomics identifies peptides for cancer vaccines; and plasma proteomics predicts patient treatment response and disease outcomes, consistently outperforming other omics modalities in multiomics studies.